Invitrogen to Presents at SBS 2006 Regional Meeting
News Feb 24, 2006
This year the SBS is honored to present Invitrogen as its premier sponsor at the Mid-Atlantic Regional Meeting. SBS president Al Kolb stated, "We are pleased to have Invitrogen play such an important part in this 2006 Mid-Atlantic Regional Meeting."
"In terms of support, I believe that this is the first time such a significant partnership has been established at one of our regional meetings."
"We’re committed to fostering collaborations and encouraging information exchange among leaders in biotech, pharma, and academia."
"As a non-profit organization, we rely on the industry’s financial and strategic partnerships, such as this cooperation from Invitrogen."
"Invitrogen is committed to developing technologies that enable drug discovery researchers to solve the increasingly complex challenges set before them," explained John Printen, Ph.D., Director of R & D for Invitrogen’s Drug Discovery Solutions business.
"The meetings that SBS presents offer scientists a great opportunity to see first-hand the advances that may carry their research through to their goals."
This meeting will provide international members and colleagues with an educational forum and the opportunity to network.
With attendance anticipated to surpass past regional meetings, the SBS Mid-Atlantic Regional is also viewed as a significant event for vendors to market new products, obtain quality leads, and be showcased as a participating exhibitor.
The two-day 2006 meeting is aimed at biotechnologists and life science screeners within both academia, and the Biotechnology/Pharmaceutical industry.
International attendees, as well as East Coast professionals, will benefit by attending tutorials and interacting with exhibiting company representatives.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE